NeuroBo Pharmaceuticals announced the completion of the last patient visit in its Phase 2a clinical trial for DA-1241, a treatment for metabolic dysfunction-associated steatohepatitis (MASH).
AI Assistant
METAVIA INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.